How to Register
- To register, press the "Login" or "Register" button on the right.
- Sign in with your scai.org username and password. If you don't have an account, click “Set Up Your Login.”
- Once registered, you will see a screen where you can add the webinar to your calendar.
Overview
Aortic stenosis may not be the whole story. Join experts for an in-depth examination of the important clinical intersection between aortic stenosis (AS) and transthyretin amyloid cardiomyopathy (ATTR-CM).
Explore the clinical overlap of AS and ATTR-CM, approaches to identifying cardiac amyloidosis in patients undergoing TAVR evaluation, opportunities for multidisciplinary workflow integration, and the evolving therapeutic landscape—including tafamidis, acoramidis, vutrisiran, and what may be ahead.
Faculty and Agenda
Monday, December 7, 2026
5:00pm Eastern, 4:00pm Central, 3:00pm Mountain, 2:00pm Pacific
 |
Mathew Maurer, MD
Moderator |
 |
Cesia Gallegos Kattan, MD, MHS
Diagnostic Pathways: Screening for Cardiac Amyloid in TAVR Patients |
 |
Jan Griffin, MD
Therapeutic Advances: Tafamidis, Acoramidis, Vutrisiran and Beyond |
 |
Christian Nitsche, MD, PhD
Multidisciplinary Care and Workflow Integration |
 |
Thomas A. Treibel, MD
Epidemiology and Clinical Overlap of AS and ATTR-CM
|
|
|
Acknowledgement of Commercial Support
This activity is supported by unrestricted educational grants from Alnylam, AstraZeneca, BridgeBio, and Pfizer.
Learning Objectives
At the conclusion of this initiative participants will be able to demonstrate the ability to:
- Recognize the prevalence and red flag indicators of ATTR-CM in patients with aortic stenosis.
- Implement a systematic diagnostic approach for suspected cardiac amyloidosis in AS patients, including appropriate use of imaging and laboratory tests, to accurately diagnose ATTR-CM before or shortly after TAVR.
- Incorporate ATTR-CM disease-modifying therapy into the care plan for TAVR patients with confirmed amyloidosis.
- Develop a multidisciplinary management plan for AS patients with ATTR-CM.
Disclosures
Individuals in control of content reported the following relevant financial relationships with ineligible companiesduring the content development process for this activity. All relevant financial relationships were mitigated beforethe start of the activity.
Planner:
Alexandra J. Lansky, MD, MSCAI: Abbott Vascular - PI; Abiomed - Advisory Board, speaker; B. Braun - PI, speaker; Boston Scientific - speaker; Emboline - Advisory Board, PI, speaker; Innovative Cardiovascular Solutions - PI; MedAlliance - consultant; Shockwave - Advisory Board, PI, speaker.
Faculty:
Cesia Gallegos Kattan, MD, MHS: Alnylam Pharmaceuticals, Inc. – consulting, advisory board; BridgeBio – consulting, speaker; Novo Norodisk AS – consulting, advisory board; Pfizer, Inc. – consulting, speaker.
Jan Griffin, MD: AstraZeneca Pharmaceuticals – consultant; BridgeBio – consultant, speaker, research support; Pfizer, Inc. – consultant, research support.
Mathew Maurer, MD: Alnylam, Inc. – research support; AstraZeneca Pharmaceuticals – consultant; Attralus – consultant; BridgeBio – consultant; Eidos, Inc. – consultant; Intellia (DSMB) – research support; Ionis – consultant; Novo Norodisk, Inc. - consultant.
Christian Nitsche, MD, PhD and Thomas A. Treibel, MD: No relevant financial relationships with ineligible companies.
Reviewers:
Nkechi Ijioma, MBBS, FSCSI: No relevant financial relationships with ineligible companies.
Staff:
Kristen Perry and Amanda Pettyjohn: No relevant financial relationships with ineligible companies.
Accredited Continuing Education Information
Accreditation Statement
The Society for Cardiovascular Angiography and Interventions (SCAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation
SCAI designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ABIM MOC
Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn up to 1.0 MOC point in the American Board of Internal Medicine (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting ABIM MOC credit.
Successful Completion
Participate in the live activity and complete the evaluation to obtain credit.
Copyright
© 2026 Society for Cardiovascular Angiography and InterventionsTM (SCAI). All rights reserved.